Orphan medicinal products

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Synonym(s)

orphan drug; orphan drugs

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Drugs for the treatment of rare diseases (orphan diseases). More than 5000 such diseases have been identified to date. The EC Regulation on orphan medicinal products came into force on 22.01.2000. This regulation contains the following regulations, among others:
  • Granting of orphan medicinal product status
  • Rare disease status can be based on both epidemiological (< 5 patients under 10,000 in the EU) and economic criteria (no chance of recovering development costs).
  • An application for orphan status can be submitted at any stage of the development of such a drug prior to application for marketing authorisation.
The EMA (European Medicines Agency) is obliged by the regulation to support companies in the development, in particular in the design and implementation of clinical studies for such drugs (protocol assistance).

General informationThis section has been translated automatically.

  • Furthermore, the granting of "orphan" status is also associated with a complete or partial exemption from fees charged by the EMA, e.g. for advice on development and for the processing of applications for authorisation and amendments (since 2006 this has only applied to small and medium-sized companies).
  • A specially appointed committee, the Committee for Orphan Medicinal Products (COMP), prepares an opinion on submitted applications for the granting of "orphan" status within 90 days, on which the Commission decides within 30 days of receipt at the latest.
  • The subsequent marketing authorisation, including the assessment of quality, efficacy and safety, will be granted later, as for other medicinal products, in a centralised procedure by the Committee for Medicinal Products for Human Use (CHMP) at the EMA with subsequent confirmation by the European Commission.
  • Since September 2005 there is now also a legal basis for "Compassionate use" programmes in Germany (AMG). This enables patients who cannot be included in clinical studies to have access to drugs that have not yet been approved. The prerequisite for this is the existence of tolerability and efficacy studies.

Authors

Last updated on: 29.10.2020